This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
by Zacks Equity Research
Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases.
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Sanofi's tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis.
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
by Zacks Equity Research
Novo Nordisk's diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday
by Zacks Equity Research
Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.
Here's Why Agios Stock Plummeted More Than 20% on Monday
by Zacks Equity Research
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
by Zacks Equity Research
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.
Grifols Stock Declines After Brookfield Drops Buyout Offer
by Zacks Equity Research
Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an aggressive form of prostate cancer.
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
by Zacks Equity Research
Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
by Zacks Equity Research
Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
by Zacks Equity Research
CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
by Zacks Equity Research
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 143.75% and 76.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 290% and 144.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.
GSK Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -50% and 13.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.
AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag
by Zacks Equity Research
AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.
Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan
by Zacks Equity Research
Apellis (APLS) stock falls on the CHMP's negative recommendation to the EMA regarding the approval of intravitreal pegcetacoplan in the EU for the treatment of geographic atrophy secondary to age-related macular degeneration.
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
by Zacks Equity Research
SpringWorks (SWTX) receives a big boost with the FDA's approval for Ogsiveo (nirogacestat) to treat adult patients with progressing desmoid tumors.